Clinical Psychiatry News - Lilly reaches Zyprexa settlement
The drugmaker Eli Lilly & Co. has agreed to pay up to $500 million to settle approximately 18,000 claims related to its atypical antipsychotic Zyprexa (olanzapine). Most of the claims stated that, before September 2003, the Zyprexa package insert did not adequately display the risk of hyperglycemia and diabetes.
Related Results
Injectable ZyprexaZyprexa WarningZyprexa filingZyprexa unveiledTexas depresses Zyprexa
In September 2003, the Food and Drug Administration required a label change for all atypical antipsychotics that added information about a relationship between diabetes and this type of medication. Zyprexa has been approved for the treatment of schizophrenia and bipolar disorder. “While we remain confident that these claims are without merit, we took this difficult step because we believe it is in the best interest of the company, the patients who depend on this medication, and their physicians,” Sidney Taurel, CEO of Eli Lilly, said in a statement. The settlement also means that any claims in which physicians are named as codefendants will be dismissed, according to Eli Lilly. Approximately 1,200 Zyprexa claims were not included in the settlement.
COPYRIGHT 2007 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
